Remarks on Modeling Host-Viral Dynamics and Treatment

[1]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[2]  M A Nowak,et al.  The evolutionary dynamics of HIV-1 quasispecies and the development of immunodeficiency disease. , 1990, AIDS.

[3]  T. Merigan,et al.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.

[4]  Alan S. Perelson,et al.  Quantitative Image Analysis of HIV-1 Infection in Lymphoid Tissue , 1996, Science.

[5]  W. Tan,et al.  Some state space models of HIV pathogenesis under treatment by anti-viral drugs in HIV-infected individuals. , 1999, Mathematical biosciences.

[6]  Russell W. Anderson,et al.  How adaptive antibodies facilitate the evolution of natural antibodies , 1996, Immunology and cell biology.

[7]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[8]  D. Kirschner,et al.  A Mathematical Model of Combined Drug Therapy of HIV Infection , 1997 .

[9]  Louis J. Picker,et al.  Changes in thymic function with age and during the treatment of HIV infection , 1998, Nature.

[10]  Ashley T. Haase,et al.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.

[11]  A S Perelson,et al.  Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. , 2000, The Journal of infectious diseases.

[12]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[13]  B. Zerhouni,et al.  Isolation of primary HIV-1 that target CD8+ T Lymphocytes using CD8 as a receptor , 2001, Nature Medicine.

[14]  Douglas D. Richman,et al.  Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel , 1996 .

[15]  D. Kirschner,et al.  Optimal control of the chemotherapy of HIV , 1997, Journal of mathematical biology.

[16]  A. Mocroft,et al.  Antiviral therapy , 1995, Nature.

[17]  Alan S. Perelson,et al.  Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..

[18]  G. F. Webb,et al.  Resistance, remission, and qualitative differences in HIV chemotherapy. , 1997, Emerging infectious diseases.

[19]  V. Harden,et al.  Chemokines and HIV–1 second receptors , 1996, Nature Medicine.

[20]  M. Bukrinsky,et al.  Other approaches , 1995, Nature.

[21]  Russell W. Anderson,et al.  Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: a worst-case dynamic analysis. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[22]  M A Nowak,et al.  Mathematical biology of HIV infections: antigenic variation and diversity threshold. , 1991, Mathematical biosciences.

[23]  José Álvarez-Ramírez,et al.  Feedback Control of the chemotherapy of HIV , 2000, Int. J. Bifurc. Chaos.

[24]  New anti-HIV drugs and treatment strategies buoy AIDS researchers. , 1996, JAMA.

[25]  F. Burnet.  The clonal selection theory of acquired immunity , 1959 .

[26]  B. Ledergerber,et al.  Levels of HIV‐infected peripheral blood cells remain stable throughout the natural history of HIV‐1 infection , 1998, AIDS.

[27]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[28]  Roy M. Anderson,et al.  Complex dynamical behaviour in the interaction between HIV and the immune system , 1989 .

[29]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[30]  Glenn F. Webb,et al.  Model of HIV-1 disease progression based on virus-induced lymph node homing and homing-induced apoptosis of CD4+ lymphocytes. , 2000 .

[31]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[32]  Chee-Jen Chang,et al.  A 12‐month study of the effects of oral zidovudine on neurodevelopmental functioning in a cohort of vertically HIV‐infected inner‐city children , 1994, AIDS.

[33]  D. Kirschner,et al.  A model for treatment strategy in the chemotherapy of AIDS. , 1996, Bulletin of mathematical biology.

[34]  A. Perelson.  Modeling the interaction of the immune system with HIV , 1989 .

[35]  A S Perelson,et al.  Role of the thymus in pediatric HIV-1 infection. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[36]  L N Cooper,et al.  Theory of an immune system retrovirus. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Nowak,et al.  Population Dynamics of Immune Responses to Persistent Viruses , 1996, Science.

[38]  M A Nowak,et al.  Models of interactions between HIV and other pathogens. , 1992, Journal of theoretical biology.

[39]  T Hraba,et al.  Application of mathematical model of immunological tolerance to HIV infection. , 1988, Folia biologica.

[40]  G. F. Webb,et al.  Understanding drug resistance for monotherapy treatment of HIV infection , 1997, Bulletin of mathematical biology.

[41]  M A Nowak,et al.  Competition between zidovudine‐sensitive and zidovudine‐resistant strains of HIV , 1992, AIDS.

[42]  W. Tan,et al.  Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies. , 1998, Mathematical biosciences.

[43]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[44]  Glenn F. Webb,et al.  Immunotherapy of HIV-1 Infection , 1998 .

[45]  D. Ho,et al.  Viral Counts Count in HIV Infection , 1996, Science.

[46]  M. Zupancic,et al.  Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. , 1997, Science.

[47]  C. Tamalet,et al.  Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma. , 1996, The Journal of infectious diseases.

[48]  R. Siliciano,et al.  Viral Dynamics in HIV-1 Infection , 1998, Cell.

[49]  M. Roos,et al.  Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. , 1992, The Journal of infectious diseases.

[50]  D. Ho,et al.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection. , 1993, Science.

[51]  Stephen J. Merrill,et al.  Modeling the interaction of HIV with cells of the immune system , 1989 .

[52]  P. Matzinger,et al.  Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells , 1996, Science.

[53]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[54]  T. O'Brien,et al.  Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. , 1992, JAMA.

[55]  A. Perelson,et al.  Dynamics of HIV infection of CD4+ T cells. , 1993, Mathematical biosciences.

[56]  Anthony S. Fauci,et al.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.

[57]  K Dietz,et al.  Analysis of a model for the pathogenesis of AIDS. , 1997, Mathematical biosciences.

[58]  S. Hammer,et al.  Zidovudine: Five Years Later , 1992, Annals of Internal Medicine.

[59]  Jon Cohen.  Chemokines Share Center Stage With Drug Therapy , 1996, Science.

[60]  A S Perelson,et al.  Target cell limited and immune control models of HIV infection: a comparison. , 1998, Journal of theoretical biology.

[61]  W. Tan,et al.  Estimation of HIV infection and incubation via state space models. , 2000, Mathematical biosciences.

[62]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[63]  S. Nagata,et al.  Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. , 1996, Blood.

[64]  M A Nowak,et al.  Coexistence and competition in HIV infections. , 1992, Journal of theoretical biology.

[65]  Denise E. Kirschner,et al.  Revisiting Early Models of the host-pathogen interactions in HIV infection , 2000 .

[66]  A. Perelson,et al.  A Model for the Immune System Response to HIV: AZT Treatment Studies , 1993 .

[67]  Thymus involution in the acquired immunodeficiency syndrome. , 1985, American journal of clinical pathology.

[68]  J. Phair,et al.  The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. , 1994, JAMA.

[69]  D. Richman.  HIV therapeutics : The new face of AIDS , 1996 .

[70]  J. Berzofsky,et al.  Antigen‐stimulated apoptotic T‐cell death in HIV infection is selective for CD4+T cells, modulated by cytokines and effected by lymphotoxin , 1996, AIDS.

[71]  E Pennisi,et al.  Antiviral Therapy: Eradicating HIV From a Patient: Not Just a Dream? , 1996, Science.

[72]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[73]  C. Janeway,et al.  Innate immunity: impact on the adaptive immune response. , 1997, Current opinion in immunology.